<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8 yL QC-&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;ff=20230729201144&amp;fc=20230708114047&amp;utm_campaign=出版-2<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;ff=20230729201144&amp;fc=20230708114047&amp;utm_campaign=pubmed-2" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 7 月 30 日星期日 00:11:44 +0000</lastbuilddate><pubDate> Sat, 29 Jul 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>从身体到心脏的组织细胞：埃尔德海姆-切斯特病累及心脏和多器官的复杂病例</title><link/>https://pubmed.ncbi.nlm.nih.gov/37515379/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230729201144&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 29:ehad458.doi: 10.1093/eurheartj/ehad458. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37515379/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37515379</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad458>10.1093/eurheartj/ehad458</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37515379</guid><pubDate> Sat, 29 Jul 2023 06:00:00 -0400</pubDate><dc:creator>安东尼奥·亚科内利</dc:creator><dc:creator>露西娅·莱西索蒂</dc:creator><dc:creator>朱塞佩·罗韦雷</dc:creator><dc:creator>奥雷里亚诺·鲁吉奥</dc:creator><dc:creator>菲利波·克雷亚</dc:creator><dc:date>2023-07-29</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>从身体到心脏的组织细胞：埃尔德海姆-切斯特病累及心脏和多器官的复杂病例</dc:title><dc:identifier>下午：37515379</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad458</dc:identifier></item><item><title>大辩论：所有无症状重度主动脉瓣狭窄患者都需要瓣膜置换术</title><link/>https://pubmed.ncbi.nlm.nih.gov/37503668/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230729201144&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 28:ehad355.doi: 10.1093/eurheartj/ehad355. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37503668/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37503668</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad355>10.1093/eurheartj/ehad355</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37503668</guid><pubDate> Fri, 28 Jul 2023 06:00:00 -0400</pubDate><dc:creator>翁伯纳德</dc:creator><dc:creator>吕克·皮拉德</dc:creator><dc:creator>朱利安·马格尼</dc:creator><dc:creator>大卫·梅西卡-泽图恩</dc:creator><dc:creator>菲利普·皮瓦罗</dc:creator><dc:creator>赫尔穆特·鲍姆加特纳</dc:creator><dc:date>2023-07-28</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>大辩论：所有无症状重度主动脉瓣狭窄患者都需要瓣膜置换术</dc:title><dc:identifier>下午：37503668</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad355</dc:identifier></item><item><title>天然基因驱动系统赋予水稻生殖隔离</title><link/>https://pubmed.ncbi.nlm.nih.gov/37499659/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230729201144&amp;v=2.17.9.post6+86293ac<description>杂种不育性限制了籼粳亚种间杂种优势杂种优势的利用。在本研究中，我们报道了籼粳杂交稻中控制雄配子不育的主要基因座RHS12的鉴定。我们发现RHS12由两个基因组成（iORF3/DUYAO 和 iORF4/JIEYAO）赋予 RHS12-i 型雄配子优先传递给后代，从而形成天然基因驱动。DUYAO 编码一种线粒体靶向蛋白，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 7 月 20 日：S0092-8674(23)00730-4.doi: 10.1016/j.cell.2023.06.023.打印前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">杂种不育性限制了籼粳亚种间杂种优势杂种优势的利用。在本研究中，我们报道了籼粳杂交稻中控制雄配子不育的主要基因座RHS12的鉴定。我们发现RHS12由两个基因组成（iORF3/DUYAO 和 iORF4/JIEYAO）赋予 RHS12-i 型雄配子优先传递给后代，从而形成自然基因驱动。DUYAO 编码一种线粒体靶向蛋白，与 OsCOX11 相互作用，触发细胞毒性和细胞死亡，而 JIEYAO 编码的蛋白质可通过直接物理相互作用将 DUYAO 重新路由至自噬体进行降解，从而使 DUYAO 解毒。进化轨迹分析表明，该系统可能在 AA 基因组 Oryza 进化枝中从头形成，并有助于不同谱系之间的生殖隔离 (RI)我们的综合结果为 RI 的遗传基础提供了机制见解，并为杂交水稻育种的战略设计提供了见解。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37499659/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37499659</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.06.023>10.1016/j.cell.2023.06.023</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37499659</guid><pubDate> Thu, 27 Jul 2023 06:00:00 -0400</pubDate><dc:creator>王超龙</dc:creator><dc:creator>王健</dc:creator><dc:creator>嘉育路</dc:creator><dc:creator>熊业辉</dc:creator><dc:creator>赵志刚</dc:creator><dc:creator>于晓文</dc:creator><dc:creator>郑晓明</dc:creator><dc:creator>李静</dc:creator><dc:creator>林其兵</dc:creator><dc:creator>任玉龙</dc:creator><dc:creator>杨虎</dc:creator><dc:creator>何晓东</dc:creator><dc:creator>李超</dc:creator><dc:creator>曾永伦</dc:creator><dc:creator>荣淼</dc:creator><dc:creator>郭马利</dc:creator><dc:creator>张博森</dc:creator><dc:creator>朱英</dc:creator><dc:creator>张云辉</dc:creator><dc:creator>唐伟杰</dc:creator><dc:creator>王云龙</dc:creator><dc:creator>郝本元</dc:creator><dc:creator>王启明</dc:creator><dc:creator>程思琪</dc:creator><dc:creator>何晓娟</dc:creator><dc:creator>姚博文</dc:creator><dc:creator>高俊文</dc:creator><dc:creator>朱旭飞</dc:creator><dc:creator>浩宇</dc:creator><dc:creator>王勇</dc:creator><dc:creator>孙彦</dc:creator><dc:creator>周春雷</dc:creator><dc:creator>董慧</dc:creator><dc:creator>马小丁</dc:creator><dc:creator>郭秀萍</dc:creator><dc:creator>刘曦</dc:creator><dc:creator>田云禄</dc:creator><dc:creator>刘世佳</dc:creator><dc:creator>王春明</dc:creator><dc:creator>程志军</dc:creator><dc:creator>江陵</dc:creator><dc:creator>周家武</dc:creator><dc:creator>郭惠山</dc:creator><dc:creator>姜立文</dc:creator><dc:creator>陶大云</dc:creator><dc:creator>柴继杰</dc:creator><dc:creator>张伟</dc:creator><dc:creator>王海洋</dc:creator><dc:creator>吴传银</dc:creator><dc:creator>万建民</dc:creator><dc:date>2023-07-27</dc:date><dc:source>细胞</dc:source><dc:title>天然基因驱动系统赋予水稻生殖隔离</dc:title><dc:identifier>下午：37499659</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.06.023</dc:identifier></item><item><title>加速减少全球心血管疾病对于实现可持续发展目标至关重要</title><link/>https://pubmed.ncbi.nlm.nih.gov/37495743/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230729201144&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 7 月 26 日。doi：10.1038/s41569-023-00912-z。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37495743/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37495743</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00912-z>10.1038/s41569-023-00912-z</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37495743</guid><pubDate> Wed, 26 Jul 2023 06:00:00 -0400</pubDate><dc:creator>丹尼尔·J·皮内罗</dc:creator><dc:creator>埃莉萨·科达托</dc:creator><dc:creator>耶利米·姆旺吉</dc:creator><dc:creator>让-吕克·艾塞勒</dc:creator><dc:creator>贾加特·纳鲁拉</dc:creator><dc:date>2023-07-26</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>加速减少全球心血管疾病对于实现可持续发展目标至关重要</dc:title><dc:identifier>下午：37495743</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00912-z</dc:identifier></item><item><title>使用 Impella 5.0/5.5 治疗接受 VT 消融的晚期心力衰竭高危患者的首次人体经验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37495284/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230729201144&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 1 日；82(5):469-471。doi:10.1016/j.jacc.2023.05.012。Epub 2023 年 5 月 20 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37495284/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37495284</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.012>10.1016/j.jacc.2023.05.012</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37495284</guid><pubDate> Wed, 26 Jul 2023 06:00:00 -0400</pubDate><dc:creator>雅库布·斯劳贝克</dc:creator><dc:creator>拉米亚·瓦贾佩</dc:creator><dc:creator>约瑟夫·西普科</dc:creator><dc:creator>-爱德华·G·索尔特斯</dc:creator><dc:creator>亚伦·J·韦斯</dc:creator><dc:creator>曼迪普·巴尔加瓦</dc:creator><dc:creator>艾曼·侯赛因</dc:creator><dc:creator>穆罕默德·坎吉</dc:creator><dc:creator>瓦利德·萨利巴</dc:creator><dc:creator>泰勒·泰根</dc:creator><dc:creator>乌萨马·M·瓦兹尼</dc:creator><dc:creator>帕斯卡莱·桑坦吉利</dc:creator><dc:date>2023-07-26</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>使用 Impella 5.0/5.5 治疗接受 VT 消融的晚期心力衰竭高危患者的首次人体经验</dc:title><dc:identifier>下午：37495284</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.012</dc:identifier></item><item><title>心血管疾病研究员的面对面与虚拟面试形式：全国培训研究员调查</title><link/>https://pubmed.ncbi.nlm.nih.gov/37495283/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230729201144&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 1 日；82(5):465-468.doi:10.1016/j.jacc.2023.05.039。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37495283/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37495283</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.039>10.1016/j.jacc.2023.05.039</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37495283</guid><pubDate> Wed, 26 Jul 2023 06:00:00 -0400</pubDate><dc:creator> ——乔纳森·R·萨利克</dc:creator><dc:creator>——艾米丽·K·泽恩</dc:creator><dc:creator>英巴尔·R·麦卡锡</dc:creator><dc:creator>保罗·塞里奥特</dc:creator><dc:creator>克里斯汀·韦斯特</dc:creator><dc:creator>普拉山·塔克</dc:creator><dc:creator>——盖比·韦斯曼</dc:creator><dc:creator>丽莎·J·罗斯·琼斯</dc:creator><dc:date>2023-07-26</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>心血管疾病研究员的面对面与虚拟面试形式：全国培训研究员调查</dc:title><dc:identifier>下午：37495283</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.039</dc:identifier></item><item><title>二叶式主动脉瓣患者主动脉扩张的机制：JACC 最先进的综述</title><link/>https://pubmed.ncbi.nlm.nih.gov/37495282/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230729201144&amp;v=2.17.9.post6+86293ac<description>二叶式主动脉瓣是最常见的先天性心脏病，使患者主动脉扩张和夹层的风险增加。主动脉扩张是一个缓慢、无声的过程，导致主动脉夹层的风险更大。所需的终生影像学监测的频率是对于临床医生和患者都很重要，并激发了广泛的研究来阐明...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 1 日；82(5):448-464.doi:10.1016/j.jacc.2022.10.042。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">二叶式主动脉瓣是最常见的先天性心脏病，使患者主动脉扩张和夹层的风险增加。主动脉扩张是一个缓慢、无声的过程，导致主动脉夹层的风险更大。所需的终生影像学监测的频率是对于临床医生和患者来说都很重要，并推动了广泛的研究，以阐明二叶式主动脉瓣主动脉病的病理生理过程。过去十年中，两个主要研究假设得到了巩固：一个支持扩张患病率增加的遗传基础，特别是对于主动脉根部，第二个支持与这些结构异常瓣膜相关的流动动力学改变对主动脉壁的破坏性影响，特别是在升主动脉中。目前的观点倾向于排除相互排斥的致病机制，认为两者都重要且重要潜在的临床相关性。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37495282/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37495282</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2022.10.042>10.1016/j.jacc.2022.10.042</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37495282</guid><pubDate> Wed, 26 Jul 2023 06:00:00 -0400</pubDate><dc:creator>何塞·F·罗德里格斯-帕洛马雷斯</dc:creator><dc:creator>莉迪亚·杜克斯·桑托伊</dc:creator><dc:creator>安德里亚·瓜拉</dc:creator><dc:creator>劳拉·加利安-盖伊</dc:creator><dc:creator>阿图罗·埃万杰利斯塔</dc:creator><dc:date>2023-07-26</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>二叶式主动脉瓣患者主动脉扩张的机制：JACC 最先进的综述</dc:title><dc:identifier>下午：37495282</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2022.10.042</dc:identifier></item><item><title>心力衰竭社区的全球挑战和全球机遇</title><link/>https://pubmed.ncbi.nlm.nih.gov/37495281/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230729201144&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 1 日；82(5):445-447.doi:10.1016/j.jacc.2023.05.043。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37495281/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37495281</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.043>10.1016/j.jacc.2023.05.043</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37495281</guid><pubDate> Wed, 26 Jul 2023 06:00:00 -0400</pubDate><dc:creator> ——亚当·D·德沃尔</dc:creator><dc:creator>拉里·艾伦</dc:creator><dc:date>2023-07-26</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>心力衰竭社区的全球挑战和全球机遇</dc:title><dc:identifier>下午：37495281</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.043</dc:identifier></item><item><title>心力衰竭患者再入院率的全球比较</title><link/>https://pubmed.ncbi.nlm.nih.gov/37495280/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230729201144&amp;v=2.17.9.post6+86293ac<description>结论：在全球范围内，住院心力衰竭患者的再入院率和死亡率很高，并且再入院率的变异性不能用医疗保健支出、死亡风险或合并症来解释。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 1 日；82(5):430-444.doi:10.1016/j.jacc.2023.05.040。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：某些司法管辖区的心力衰竭 (HF) 再入院率较低。然而，缺乏国际比较，可以作为确定区域患者管理策略的基础，并可共享这些策略以改善结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究旨在总结各国住院心力衰竭患者的 30 天和 1 年全因再入院率和死亡率，并探讨全球范围内的潜在差异。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们使用 MEDLINE、Embase 和 CENTRAL 对 2010 年 1 月至 2021 年 3 月期间发表的有再入院或死亡风险的住院成人心力衰竭患者的观察报告进行了系统回顾和荟萃分析。我们使用随机效应模型，并通过荟萃回归评估异质性来源。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：总共纳入了 24 篇报告 30 天再入院的论文和 23 篇报告 1 年再入院的论文。在 150 万高危人群中，13.2%（95% CI：10.5%-16.1%）在 30 天内再入院，并且1 年内死亡率为 35.7% (95% CI: 27.1%-44.9%)。共有 33 篇论文报告了 30 天死亡率，45 篇论文报告了 1 年死亡率。在 150 万人中，7.6% (95%) 因心力衰竭住院。 ) CI: 6.1%-9.3%) 在 30 天内死亡，23.3% (95% CI: 20.8%-25.9%) 在 1 年内死亡。各国国内生产总值、占国内生产总值的比例无法解释各国之间风险的巨大差异国内产品在医疗保健方面的支出以及基尼系数。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在全球范围内，住院心力衰竭患者的再入院率和死亡率很高，并且再入院率的变异性不能用医疗保健支出、死亡风险或合并症来解释。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37495280/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37495280</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.040>10.1016/j.jacc.2023.05.040</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37495280</guid><pubDate> Wed, 26 Jul 2023 06:00:00 -0400</pubDate><dc:creator>法里德·福鲁坦</dc:creator><dc:creator>丹尼尔·G·雷纳</dc:creator><dc:creator>希瑟·J·罗斯</dc:creator><dc:creator>塔玛拉·埃勒</dc:creator><dc:creator>阿纳尼亚·斯里瓦斯塔瓦</dc:creator><dc:creator>申修正</dc:creator><dc:creator>阿卜杜拉·马利克</dc:creator><dc:creator>哈苏克·贝尼帕尔</dc:creator><dc:creator>克拉丽莎·余</dc:creator><dc:creator>刘子轩</dc:creator><dc:creator>约书亚·G·李</dc:creator><dc:creator>鲁道夫·罗查</dc:creator><dc:creator>Peter C Austin更多</dc:creator><dc:creator>丹尼尔·利维</dc:creator><dc:creator>詹妮弗·E·何</dc:creator><dc:creator>约翰·JV·麦克默里</dc:creator><dc:creator>Faiez Zannad更多</dc:creator><dc:creator>乔治·汤姆林森</dc:creator><dc:creator>约翰·斯珀图斯</dc:creator><dc:creator>道格拉斯·李</dc:creator><dc:date>2023-07-26</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>心力衰竭患者再入院率的全球比较</dc:title><dc:identifier>下午：37495280</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.040</dc:identifier></item><item><title> C 反应蛋白在心力衰竭中的不断变化的作用：对心血管疾病患者的影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/37495279/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230729201144&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 1 日；82(5):427-429.doi:10.1016/j.jacc.2023.05.036。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37495279/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37495279</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.036>10.1016/j.jacc.2023.05.036</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37495279</guid><pubDate> Wed, 26 Jul 2023 06:00:00 -0400</pubDate><dc:creator>伊什瓦拉尔·贾拉尔</dc:creator><dc:creator>伊莫·埃邦</dc:creator><dc:date>2023-07-26</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>C 反应蛋白在心力衰竭中的不断变化的作用：对心血管疾病患者的影响</dc:title><dc:identifier>下午：37495279</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.036</dc:identifier></item><item><title> C 反应蛋白与心血管疾病患者发生心力衰竭的风险</title><link/>https://pubmed.ncbi.nlm.nih.gov/37495278/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230729201144&amp;v=2.17.9.post6+86293ac<description>结论：在已确诊的 CVD 患者中，CRP 是发生心力衰竭的独立风险标志物。这些数据支持正在进行的试验工作，以评估抗炎药物是否可以减轻心力衰竭的负担。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 1 日；82(5):414-426.doi:10.1016/j.jacc.2023.05.035。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：患有心血管疾病（CVD）的患者发生心力衰竭（HF）的风险很高，这可能部分反映了全身炎症的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究的目的是确定已确诊 CVD 患者中 C 反应蛋白 (CRP) 与心力衰竭之间的关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：前瞻性 UCC-SMART（乌得勒支心血管队列 - ARTerial 疾病第二表现）队列中已确诊有 CVD 但无流行性心力衰竭的患者纳入其中 (n = 8,089)。心力衰竭事件定义为首次因心力衰竭住院。使用针对已确定的危险因素（即年龄、性别、心肌梗塞、吸烟、糖尿病、体重指数、血压、胆固醇和肾功能）进行调整的Cox比例风险模型来评估CRP和心力衰竭事件。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在中位随访 9.7 年（IQR 5.4-14.1 年）期间，观察到 810 例心力衰竭病例（发病率 1.01/100 人年）。较高的 CRP 与心力衰竭风险增加独立相关：HR每 1 mg/L：1.10（95% CI：1.07-1.13），最后一个 CRP 四分位数与第一个 CRP 四分位数：2.22（95% CI：1.76-2.79）。对于心力衰竭和降低（HR：1.09； 95% CI：1.04-1.14）和保留射血分数（HR：1.12；95% CI：1.07-1.18）（差异 P = 0.137）。对药物使用和临时心肌梗死进行额外调整并没有减弱这种关联，并且CRP 测量后 15 年后，这种关联仍然保持一致。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在已确诊的 CVD 患者中，CRP 是发生心力衰竭的独立风险标志物。这些数据支持正在进行的试验工作，以评估抗炎药物是否可以减轻心力衰竭的负担。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37495278/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37495278</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.035>10.1016/j.jacc.2023.05.035</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37495278</guid><pubDate> Wed, 26 Jul 2023 06:00:00 -0400</pubDate><dc:creator>帕斯卡·M·伯格</dc:creator><dc:creator>斯特凡·考德斯塔尔</dc:creator><dc:creator>阿伦德·莫斯特德</dc:creator><dc:creator>埃尔努德·TL·菲奥莱特</dc:creator><dc:creator>马丁·泰拉</dc:creator><dc:creator>曼农·G·范德米尔</dc:creator><dc:creator>马丁·J·克莱默</dc:creator><dc:creator>——弗兰克·L·J·维瑟伦</dc:creator><dc:creator>——保罗·M·里德克</dc:creator><dc:creator>詹尼克·安·多雷斯坦</dc:creator><dc:creator>UCC-SMART研究组</dc:creator><dc:date>2023-07-26</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>C 反应蛋白与心血管疾病患者发生心力衰竭的风险</dc:title><dc:identifier>下午：37495278</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.035</dc:identifier></item><item><title>较低他汀类药物剂量的联合治疗和 LDL-C 目标竞赛：明显的赢家？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37495277/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230729201144&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 1 日；82(5):411-413.doi:10.1016/j.jacc.2023.06.003。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37495277/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37495277</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.003>10.1016/j.jacc.2023.06.003</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37495277</guid><pubDate> Wed, 26 Jul 2023 06:00:00 -0400</pubDate><dc:creator>奥里·本-耶胡达</dc:creator><dc:date>2023-07-26</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>较低他汀类药物剂量的联合治疗和 LDL-C 目标竞赛：明显的赢家？</dc:title><dc:identifier>下午：37495277</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.003</dc:identifier></item><item><title>经皮冠状动脉介入治疗患者的联合降脂治疗</title><link/>https://pubmed.ncbi.nlm.nih.gov/37495276/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230729201144&amp;v=2.17.9.post6+86293ac<description>结论：在临床实践中，依折麦布和中等强度他汀类药物联合降脂治疗与接受药物洗脱支架植入治疗的患者良好的临床结果和药物依从性相关（CONNECT DES 注册中心；NCT04715594）。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 1 日；82(5):401-410.doi:10.1016/j.jacc.2023.05.042。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：RACING（他汀类药物单一疗法与他汀类药物/依折麦布组合治疗高危心血管疾病的降脂功效和安全性的随机比较）试验检查了中等强度他汀类药物和依折麦布联合治疗对动脉粥样硬化性心血管疾病患者的效果与高强度他汀类药物单一疗法相比。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：这项观察性研究旨在评估 RACING 试验中使用的 2 种治疗策略在临床实践中的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：治疗权重逆概率稳定后，从全国队列数据库中筛选出 72,050 例药物洗脱支架植入后服用瑞舒伐他汀的患者：其中 10,794 例患者接受瑞舒伐他汀 10 mg 加依折麦布 10 mg（联合降脂治疗）以及 61,256 名接受瑞舒伐他汀 20 mg 单药治疗的患者。根据 RACING 试验，主要终点是心血管死亡、心肌梗死、冠状动脉血运重建、心力衰竭住院治疗或非致命性中风的 3 年复合事件。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：联合降脂治疗与较低的主要终点发生率相关（高强度他汀类药物单一治疗为 11.6% vs 15.2%；HR：0.75；95% CI：0.70-0.79；P &lt; 0.001）。高强度他汀类药物单药治疗、联合降脂治疗与他汀类药物停药较少（6.5% vs 7.6%；HR：0.85；95% CI：0.78–0.94：P &lt; 0.001）和新发糖尿病发生率较低相关需要药物治疗（7.7% vs 9.6%；HR：0.80；95% CI：0.72-0.88；P &lt; 0.001）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在临床实践中，依折麦布和中等强度他汀类药物联合降脂治疗与接受药物洗脱支架植入治疗的患者良好的临床结果和药物依从性相关（CONNECT DES 注册中心；NCT04715594）。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37495276/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37495276</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.042>10.1016/j.jacc.2023.05.042</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37495276</guid><pubDate> Wed, 26 Jul 2023 06:00:00 -0400</pubDate><dc:creator>李承俊</dc:creator><dc:creator>在弘柱</dc:creator><dc:creator>昭熙公园</dc:creator><dc:creator>金忠基</dc:creator><dc:creator>崔东雨</dc:creator><dc:creator>洪成镇</dc:creator><dc:creator>安哲民</dc:creator><dc:creator>金正善</dc:creator><dc:creator>金秉国</dc:creator><dc:creator>高英国</dc:creator><dc:creator>崔东勋</dc:creator><dc:creator>张良洙</dc:creator><dc:creator>南正模</dc:creator><dc:creator>洪明基</dc:creator><dc:date>2023-07-26</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>经皮冠状动脉介入治疗患者的联合降脂治疗</dc:title><dc:identifier>下午：37495276</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.042</dc:identifier></item><item><title>皮下植入式心脏复律除颤器系统的长期安全性和有效性</title><link/>https://pubmed.ncbi.nlm.nih.gov/37495275/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230729201144&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 1 日；82(5):398-400.doi:10.1016/j.jacc.2023.05.037。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37495275/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37495275</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.037>10.1016/j.jacc.2023.05.037</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37495275</guid><pubDate> Wed, 26 Jul 2023 06:00:00 -0400</pubDate><dc:creator>乔纳森·斯坦伯格</dc:creator><dc:creator>瓦伦蒂娜·库蒂法</dc:creator><dc:date>2023-07-26</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>皮下植入式心脏复律除颤器系统的长期安全性和有效性</dc:title><dc:identifier>下午：37495275</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.037</dc:identifier></item><item><title>皮下植入式心脏复律除颤器系统的批准后研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37495274/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230729201144&amp;v=2.17.9.post6+86293ac<description>结论：在迄今为止最大规模的 S-ICD 前瞻性研究中，尽管队列的合并症比大多数以前的试验更多，但所有研究终点均得到满足。并发症发生率低，休克疗效高。这些结果表明 5 年效果S-ICD 对大量不同 S-ICD 接受者的安全性和有效性（皮下植入式心脏复律除颤器 [S-ICD] 系统批准后研究 [PAS]；NCT01736618）。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 1 日；82(5):383-397.doi:10.1016/j.jacc.2023.05.034。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：皮下植入式心律转复除颤器（S-ICD）的开发是为了避免与经静脉植入式心律转复除颤器（TV-ICD）导线相关的并发症。该装置的安全性和有效性先前已在非典型临床患者或有限的随访中得到证实。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目标：S-ICD PAS（皮下植入式心脏复律除颤器系统批准后研究）是一项真实世界、多中心、美国中心注册中心，旨在评估不同患者群体的长期 S-ICD 安全性和有效性和植入中心。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：患者在美国 86 个具有标准 S-ICD 适应症的中心入组，观察长达 5 年。疗效终点为首次和最终休克疗效。安全终点为与 S-ICD 系统或植入程序直接相关的并发症。使用预先指定的绩效目标进行评估。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：共有 1,643 名患者前瞻性入组，中位随访时间为 4.2 年。所有预设的安全性和有效性终点目标均得到满足。室性心动过速或心室颤动离散发作的电击有效率为 98.4%，并且他们确实做到了这一点。随访年数间无显着差异 (P = 0.68)。S-ICD 相关和电极相关的无并发症率分别为 93.4% 和 99.3%。只有 1.6% 的患者将其装置更换为 TV-ICD . 满足起搏需求。累积全因死亡率为 21.7%。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在迄今为止最大规模的 S-ICD 前瞻性研究中，尽管队列的合并症比大多数以前的试验更多，但所有研究终点均得到满足。并发症发生率低，休克疗效高。这些结果表明 5 年效果S-ICD 对大量不同 S-ICD 接受者的安全性和有效性（皮下植入式心脏复律除颤器 [S-ICD] 系统批准后研究 [PAS]；NCT01736618）。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37495274/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37495274</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.034>10.1016/j.jacc.2023.05.034</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37495274</guid><pubDate> Wed, 26 Jul 2023 06:00:00 -0400</pubDate><dc:creator>迈克尔·R·戈尔德</dc:creator><dc:creator>迈克尔·F·埃尔-查米</dc:creator><dc:creator>马丁·C·伯克</dc:creator><dc:creator>Gaurav A Upadhyay更多</dc:creator><dc:creator>马克·J·尼鲍尔</dc:creator><dc:creator>乔丹·普鲁特金</dc:creator><dc:creator>约翰·M·赫尔</dc:creator><dc:creator>史蒂文·库塔莱克</dc:creator><dc:creator>杰·L·迪纳曼</dc:creator><dc:creator>布拉德利·P·奈特</dc:creator><dc:creator>——吉尔·利</dc:creator><dc:creator>林赛·卢卡斯</dc:creator><dc:creator>——内森·卡特</dc:creator><dc:creator>艾米·J·布里斯本</dc:creator><dc:creator>约翰·D·阿斯博</dc:creator><dc:creator>劳尔·韦斯</dc:creator><dc:creator>S-ICD 系统批准后研究调查人员</dc:creator><dc:date>2023-07-26</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>皮下植入式心脏复律除颤器系统的批准后研究</dc:title><dc:identifier>下午：37495274</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.034</dc:identifier></item><item><title>模拟导致神经胶质瘤的表观遗传损伤</title><link/>https://pubmed.ncbi.nlm.nih.gov/37494934/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230729201144&amp;v=2.17.9.post6+86293ac<description>破坏调控元件的表观遗传损伤代表了潜在的癌症驱动因素。然而，我们缺乏验证其致瘤影响的实验模型。在这里，我们对异柠檬酸脱氢酶突变型神经胶质瘤中出现的畸变进行建模，这些神经胶质瘤表现出 DNA 高甲基化。这些癌基因经常被甲基化破坏。我们证明小鼠少突胶质细胞祖细胞中同线性绝缘子的破坏...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 7 月 20 日：S0092-8674(23)00729-8.doi: 10.1016/j.cell.2023.06.022.打印前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">破坏调控元件的表观遗传损伤代表了潜在的癌症驱动因素。然而，我们缺乏验证其致瘤影响的实验模型。在这里，我们对异柠檬酸脱氢酶突变型神经胶质瘤中出现的畸变进行建模，这些神经胶质瘤表现出 DNA 高甲基化。这些癌基因经常被甲基化破坏。我们证明，小鼠少突胶质细胞祖细胞 (OPC) 中同线性绝缘子的破坏允许 OPC 特异性增强子接触并诱导 Pdgfra，从而增加增殖。Cdkn2a 肿瘤抑制因子的甲基化依赖性沉默，与 OPC 中绝缘子的损失相配合. Pdgfra 绝缘子和 Cdkn2a 的协调失活驱动体内神经胶质瘤发生。神经胶质瘤风险但使小鼠建模复杂化。我们的研究证明了复发性表观遗传损伤在体外驱动 OPC 增殖和体内神经胶质瘤发生的能力。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37494934/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37494934</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.06.022>10.1016/j.cell.2023.06.022</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37494934</guid><pubDate> Wed, 26 Jul 2023 06:00:00 -0400</pubDate><dc:creator>吉尔伯特·J·拉赫姆</dc:creator><dc:creator>瑙曼·M·贾韦德</dc:creator><dc:creator>凯特琳·普奥罗</dc:creator><dc:creator>辛守惠</dc:creator><dc:creator>沃尔克霍夫施塔特</dc:creator><dc:creator>莎拉·E·约翰斯通</dc:creator><dc:creator>布拉德利·伯恩斯坦</dc:creator><dc:date>2023-07-26</dc:date><dc:source>细胞</dc:source><dc:title>模拟导致神经胶质瘤的表观遗传损伤</dc:title><dc:identifier>下午：37494934</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.06.022</dc:identifier></item><item><title>肌钙蛋白和怀孕</title><link/>https://pubmed.ncbi.nlm.nih.gov/37494028/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230729201144&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 7 月 26 日。doi：10.1001/jamacardio.2023.2109。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37494028/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37494028</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2109>10.1001/jamacardio.2023.2109</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37494028</guid><pubDate> Wed, 26 Jul 2023 06:00:00 -0400</pubDate><dc:creator>伊娃·弗雷纳斯</dc:creator><dc:creator>——米凯尔·德尔伯格</dc:creator><dc:date>2023-07-26</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>肌钙蛋白和怀孕</dc:title><dc:identifier>下午：37494028</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2109</dc:identifier></item><item><title>临床试验注册和报告的多样性——我们的现状和未来的道路</title><link/>https://pubmed.ncbi.nlm.nih.gov/37494022/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230729201144&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 7 月 26 日。doi：10.1001/jamacardio.2023.2106。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37494022/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37494022</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2106>10.1001/jamacardio.2023.2106</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37494022</guid><pubDate> Wed, 26 Jul 2023 06:00:00 -0400</pubDate><dc:creator>安德鲁·法布</dc:creator><dc:creator>查尔斯·J·维维亚诺</dc:creator><dc:creator>——米歇尔·E·塔弗</dc:creator><dc:date>2023-07-26</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>临床试验注册和报告的多样性——我们的现状和未来的道路</dc:title><dc:identifier>下午：37494022</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2106</dc:identifier></item><item><title>肌钙蛋白和怀孕-回复</title><link/>https://pubmed.ncbi.nlm.nih.gov/37494021/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230729201144&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 7 月 26 日。doi：10.1001/jamacardio.2023.2112。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37494021/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37494021</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2112>10.1001/jamacardio.2023.2112</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37494021</guid><pubDate> Wed, 26 Jul 2023 06:00:00 -0400</pubDate><dc:creator>阿努姆·米哈斯</dc:creator><dc:creator>伊丽莎白塞尔文</dc:creator><dc:date>2023-07-26</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>肌钙蛋白和怀孕-回复</dc:title><dc:identifier>下午：37494021</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2112</dc:identifier></item><item><title>老年患者、女性以及少数族裔个体参加瓣膜性心脏病临床试验：系统评价</title><link/>https://pubmed.ncbi.nlm.nih.gov/37494015/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230729201144&amp;v=2.17.9.post6+86293ac<description>结论和相关性：本综述发现，在过去 20 年中，女性和少数族裔个体在北美瓣膜性心脏病临床试验中的代表性仍然不足。需要开展进一步的工作来改进种族和民族数据的报告，并解决障碍针对老年患者、女性以及少数种族和族裔个体的试验招募。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。2023 年 7 月 26 日。doi：10.1001/jamacardio.2023.2098。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：心血管临床试验中老年患者、女性和少数族裔个体的代表性不足，限制了试验结果的普遍性以及获得新疗法和治疗策略的包容性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：报告研究瓣膜性心脏病治疗的临床试验中老年患者、女性以及少数族裔个体的代表性的时间趋势。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">证据审查：在 PubMed 和 ClinicalTrials.gov 搜索后，纳入了 2005 年至 2020 年间发表的所有已发表的临床试验，招募了超过 100 名患有任何瓣膜性心脏病的成年人。收集了纳入研究中报告的年龄、性别、种族和民族的数据。根据发表日期，试验被分配到 4 个时间段，并分析了老年患者、女性以及少数族裔个体的时间趋势。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> FINDINGS: A total of 139 clinical trials with 51 527 participants were identified. Of these trials, 103 (74%) investigated aortic valve disease and the remainder mitral valve disease. Overall, 63 trials (45.3%) enrolled patients only in Europe, 24 (17.3%) only in North America, and 19 (13.7%) in multiple geographical regions. The weighted mean (SD) age of enrolled patients was 68.4 (11.4) years, increasing nonsignificantly from 61.9 (5.9) years in 2005-2008 to 72.8 (9.6) years in 2017-2020 (P = .09 for trend). The overall proportion of women enrolled in valvular heart disease trials was 41.1%, with no significant changes over time. Data on race and ethnicity of trial participants were reported in 13 trials (9.4%), in which trial-level representation of American Indian/Alaska Native, Asian, Black/African American, Hispanic, and Native Hawaiian/Pacific Islander patients ranged from 0.27% to 43.9%. There were no significant temporal trends noted in the enrollment of racial and ethnic minority populations. The representation of women in clinical trials was positively associated with enrollment rates of older patients and underrepresented racial and ethnic groups. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS AND RELEVANCE: This review found that over the past 2 decades, women and racial and ethnic minority individuals have remained underrepresented in North American valvular heart disease clinical trials. Further work is needed to improve the reporting of race and ethnicity data and address barriers to trial enrollment for older patients, women, and racial and ethnic minority individuals.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37494015/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37494015</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.2098>10.1001/jamacardio.2023.2098</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37494015</guid><pubDate> Wed, 26 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Kriyana P Reddy</dc:creator><dc:creator> Michela Faggioni</dc:creator><dc:creator> Lauren A Eberly</dc:creator><dc:creator> Rim Halaby</dc:creator><dc:creator> Monika Sanghavi</dc:creator><dc:creator> Jennifer Lewey</dc:creator><dc:creator> Roxana Mehran</dc:creator><dc:creator> Megan Coylewright</dc:creator><dc:creator> Howard C Herrmann</dc:creator><dc:creator> Jay Giri</dc:creator><dc:creator> Alexander C Fanaroff</dc:creator><dc:creator> Ashwin S Nathan</dc:creator><dc:date> 2023-07-26</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Enrollment of Older Patients, Women, and Racial and Ethnic Minority Individuals in Valvular Heart Disease Clinical Trials: A Systematic Review</dc:title><dc:identifier> pmid:37494015</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2098</dc:identifier></item><item><title> Association of Longer Leukocyte Telomere Length With Cardiac Size, Function, and Heart Failure</title><link/> https://pubmed.ncbi.nlm.nih.gov/37494011/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230729201144&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS AND RELEVANCE: In this cross-sectional study, longer LTL was associated with a larger heart with better cardiac function in middle age, which could potentially explain the observed lower risk of incident HF. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Jul 26:e232167. doi: 10.1001/jamacardio.2023.2167. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> IMPORTANCE: Longer leukocyte telomere length (LTL) is associated with a lower risk of adverse cardiovascular outcomes. The extent to which variation in LTL is associated with intermediary cardiovascular phenotypes is unclear. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVE: To evaluate the associations between LTL and a diverse set of cardiovascular imaging phenotypes. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DESIGN, SETTING, AND PARTICIPANTS: This is a population-based cross-sectional study of UK Biobank participants recruited from 2006 to 2010. LTL was measured using a quantitative polymerase chain reaction method. Cardiovascular measurements were derived from cardiovascular magnetic resonance using machine learning. The median (IQR) duration of follow-up was 12.0 (11.3-12.7) years. The associations of LTL with imaging measurements and incident heart failure (HF) were evaluated by multivariable regression models. Genetic associations between LTL and significantly associated traits were investigated by mendelian randomization. Data were analyzed from January to May 2023. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> EXPOSURE: LTL. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> MAIN OUTCOMES AND MEASURES: Cardiovascular imaging traits and HF. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Of 40 459 included participants, 19 529 (48.3%) were men, and the mean (SD) age was 55.1 (7.6) years. Longer LTL was independently associated with a pattern of positive cardiac remodeling (higher left ventricular mass, larger global ventricular size and volume, and higher ventricular and atrial stroke volumes) and a lower risk of incident HF (LTL fourth quartile vs first quartile: hazard ratio, 0.86; 95% CI, 0.81-0.91; P = 1.8 × 10-6). Mendelian randomization analysis suggested a potential causal association between LTL and left ventricular mass, global ventricular volume, and left ventricular stroke volume. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS AND RELEVANCE: In this cross-sectional study, longer LTL was associated with a larger heart with better cardiac function in middle age, which could potentially explain the observed lower risk of incident HF.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37494011/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">37494011</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC10372756/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230729201144&v=2.17.9.post6+86293ac">PMC10372756</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.2167>10.1001/jamacardio.2023.2167</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37494011</guid><pubDate> Wed, 26 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Nay Aung</dc:creator><dc:creator> Qingning Wang</dc:creator><dc:creator> Stefan van Duijvenboden</dc:creator><dc:creator> Richard Burns</dc:creator><dc:creator> Svetlana Stoma</dc:creator><dc:creator> Zahra Raisi-Estabragh</dc:creator><dc:creator> Selda Ahmet</dc:creator><dc:creator> Elias Allara</dc:creator><dc:creator> Angela Wood</dc:creator><dc:creator> Emanuele Di Angelantonio</dc:creator><dc:creator> John Danesh</dc:creator><dc:creator> Patricia B Munroe</dc:creator><dc:creator> Alistair Young</dc:creator><dc:creator> Nicholas C Harvey</dc:creator><dc:creator> Veryan Codd</dc:creator><dc:creator> Christopher P Nelson</dc:creator><dc:creator> Steffen E Petersen</dc:creator><dc:creator> Nilesh J Samani</dc:creator><dc:date> 2023-07-26</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Association of Longer Leukocyte Telomere Length With Cardiac Size, Function, and Heart Failure</dc:title><dc:identifier> pmid:37494011</dc:identifier><dc:identifier> pmc:PMC10372756</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2167</dc:identifier></item></channel></rss>